External beam radiotherapy as definitive treatment for prostate cancer

Minerva Urologica e Nefrologica

Volumn 55, Issue 4, 2003, Pages 263-275

  Sosa, M ^a   Sanguineti, G ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Androgen antagonists; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; FLUTAMIDE; GOSERELIN; LEUPRORELIN;

ADVANCED CANCER; BEAM THERAPY; BRACHYTHERAPY; CANCER CONTROL; DOSE RESPONSE; DOSIMETRY; HUMAN; MALE; MORBIDITY; OUTCOMES RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; REVIEW; SALVAGE THERAPY; SEXUAL DYSFUNCTION; TREATMENT FAILURE; TREATMENT PLANNING; URINARY DYSFUNCTION;

ANDROGEN ANTAGONISTS; BIOPSY; BRACHYTHERAPY; FORECASTING; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT FAILURE;

EID: 1542288358     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Sanguineti G, Franzone P, Culp LR, Marcenaro M, Barra S, Vitale V. Radiotherapy after prostatectomy. Tumori. 2002;88:445-52.
2. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years follow-up, Int J Radiat Oncol Biol Phys 2002;54:427-35.
3. Zietman A, Thakral H, Skowronski U, Shipley W. Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:1152-9.
4. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-80.
5. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:1011-8.
6. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000;55:85-90.
7. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997;79:337-44.
8. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-604.
9. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
11. Zelefsky M, Fuks Z, Chan H, Ling C, Hunt M, Leibel S. Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S149-50.
12. Yock TI, Zietman AL, Shipley WU, Thakral HK, Coen JJ. Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:420-26.
13. Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A et al. J Urol 2003;169:2160-5.
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
15. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81. Erratum in: J Urol 2001;166:1839.
16. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81. Erratum in: J Urol 2001;166:1839.
17. Pollack A, Horwitz EM, Movsas B, Hanlon AL. Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. Urol Clin North Am 2003;30:337-49.
18. Michalski JM (guest editor). Introduction: locally advanced prostate cancer. Semin Radiat Oncol 2003;13:85-6.
19. Pollack A, Cowen D, Troncoso P, Zagars G, von Eschenbach AC, Meistrich ML et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, Bcl-2, Bax, and Bcl-x. Cancer 2003;97:1630-8.
20. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery? Urol Clin North Am 2003;3:315-30.
21. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
22. Pickles T, Charmaine Kim-Sing MB, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57:11-8.
23. Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 2002;53:304-5.
24. Sandler HM, Dunn RL, McLaughlin W, Hayman JA, Sullivan MA, Taylor JMG. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000;48:629-33.
25. D'Amico AV, Cole K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73.
26. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
27. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Councial Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1999;79:235-46.
28. Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach III M. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:1073-8.
29. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45:624-32.
30. Crook JM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997;79:81-9.
31. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
32. Forman JD, Duclos M, Shamsa F, Porter AT, Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study, Int J Radiat Oncol Biol Phys 1996;34:655-2.
33. Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:31-9.
34. Pollack A, Zagars G, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002;54:677-85.
35. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-67.
36. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999;17:1155-63.
37. Eastham JA, DiBlasio CJ, Scardino PT. Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy. Curr Urol Rep 2003;4:211-5.
38. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 2000;164:1998-2001.
39. Grossfeld GD, Li YP, Lubeck DP, Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology 2002;60 (Suppl 3A):57-63.
40. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997;15:230-8.
41. Sanguineti G, Agostinelli S, Foppiano F, Franzone P, Garelli S, Marcenaro M et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002;86:1843-7.
42. Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28:811-9.
43. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-8.
44. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Nat Cancer Inst 2000;92:1582-92.
45. Cozzarini C, Fiorino C, Ceresoli GL, Cattaneo GM, Bolognesi A, Calandrino R et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 2003;55:688-94.
46. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
47. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
48. Hanks G, Lu J, Machtay M, Venkatesan V, Pinover W, Byhard R et al. RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000;48:112.
49. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
50. rd annual ASTRO meeting San Francisco, CA, November 4-8, 2001. Int J Radiat Oncol Biol Phys 2001;51:3.
51. Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002;94:362-7.
52. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002;8:67.
53. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003;169:974-80.
54. Peschel RE, Colberg JW. Surgery, brachytherapy, and external beam radiation therapy for early prostate cancer. Lancet 2003;4:233-41.
55. Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
56. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
57. Peschel RE, Han S, Colberg J. Ultrasound guided transperineal implant (IMP) versus radical prostatectomy (RP) for early prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51 (Suppl 1):292.
58. Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999;5:301-6.
59. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-50.
60. Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ Jr. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 2000;164(3 Pt 1):738-41; discussion 741-3.
61. Dattoli M, Wallner K, True L, Sorace R, Koval J, Cash J et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999;45:853-6.
62. Merrick GS, Butler B, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Cancer J 2000;8:322-7.
63. Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-78.
64. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003;169:1643-52.
65. Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implants: iodine-125 vs palladium-103. Radiat Oncol Invest 1999;7:278-88.
66. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology 2000;55:91-96.
67. Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. Oncology 2003;17:5262; discussion 62, 67-70, 73.
68. Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893-902.